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Abstract:
Background: HIV infection is a recognized risk factor for young stroke but the exact
mechanisms are poorly understood. We studied the clinical, radiologic and histologic
features of HIV-related ischemic stroke to gain insight into the disease mechanisms.
Methods: We conducted a prospective, in-depth analysis of adult ischemic stroke
patients presenting to Queen Elizabeth Central Hospital, Blantyre, Malawi, in 2011.
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Results: We recruited 64 HIV positive and 107 HIV negative patients. Those with HIV
were significantly younger (p<0.001) and less likely to have established vascular risk
factors. Patients with HIV were more likely to have large artery disease (21% versus
10%; p <0.001). The commonest etiology was HIV-associated vasculopathy (24
[38%]), followed by opportunistic infections (16[25%]). Sixteen out of 64 (25%) had a
stroke soon after starting antiretroviral therapy (ART), suggesting an immune
reconstitution-like syndrome. In this group CD4+ T-lymphocyte count was low, despite
a significantly lower HIV viral load in those recently started on treatment (p<0.001).
Conclusions: HIV-associated vasculopathy and opportunistic infections are common
causes of HIV-related ischemic stroke. Furthermore, subtypes of HIV-associated
vasculopathy may manifest as a result of an immune reconstitution-like syndrome after
starting ART.  A better understanding of this mechanism may point towards new
treatments.
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Abstract 125 
  126 
Background: HIV infection is a recognized risk factor for young stroke but the exact mechanisms are 127 
poorly understood. We studied the clinical, radiologic and histologic features of HIV-related ischemic 128 
stroke to gain insight into the disease mechanisms. 129 
Methods: We conducted a prospective, in-depth analysis of adult ischemic stroke patients 130 
presenting to Queen Elizabeth Central Hospital, Blantyre, Malawi, in 2011.  131 
Results: We recruited 64 HIV positive and 107 HIV negative patients. Those with HIV were 132 
significantly younger (p<0.001) and less likely to have established vascular risk factors. Patients with 133 
HIV were more likely to have large artery disease (21% versus 10%; p <0.001). The commonest 134 
etiology was HIV-associated vasculopathy (24 [38%]), followed by opportunistic infections (16[25%]). 135 
Sixteen out of 64 (25%) had a stroke soon after starting antiretroviral therapy (ART), suggesting an 136 
immune reconstitution-like syndrome. In this group CD4+ T-lymphocyte count was low, despite a 137 
significantly lower HIV viral load in those recently started on treatment (p<0.001).  138 
Conclusions: HIV-associated vasculopathy and opportunistic infections are common causes of HIV-139 
related ischemic stroke. Furthermore, subtypes of HIV-associated vasculopathy may manifest as a 140 
result of an immune reconstitution-like syndrome after starting ART.  A better understanding of this 141 
mechanism may point towards new treatments. 142 
 143 
Key words:  Stroke, Vasculopathy, HIV, Africa, Immune reconstitution syndrome  144 
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Introduction  145 
Stroke incidence in low-to-middle income countries is increasing, especially in young populations.[1] 146 
In many of these regions, HIV is prevalent, and younger populations are more likely to have 147 
infectious causes of stroke.[2] 148 
We recently showed that HIV infection makes a major contribution to the overall stroke burden 149 
(Population Attributable Fraction 15%) in Malawi.[2] It was the second leading risk factor overall 150 
(behind hypertension), and the most important among young stroke patients (Population 151 
Attributable Fraction 42%). Starting antiretroviral (ART) treatment appeared to contribute to stroke 152 
risk in the very immunosuppressed, but the mechanism of this is unknown.[2] Previous reports have 153 
shown that opportunistic infections, coagulopathy and cardio-thromboembolism are important 154 
etiologies to consider.[3] In addition, HIV infection may directly lead to HIV-associated vasculopathy 155 
via inflammatory intermediaries.[4] The term vasculopathy is defined as intimal hyperplasia more than 156 
expected for age, and thus encompasses several pathologic phenotypes of stroke found in HIV infection 157 
including, 1) HIV associated accelerated atherosclerosis, 2) non-atherosclerotic vasculopathy 158 
(patients have non-vasculitic abnormalities, with intimal hyperplasia that can progress to stenosis or 159 
aneurysmal dilatation) 3) HIV-associated vasculitis, and 4) small vessel disease.[5] Our understanding 160 
of the pathologic mechanisms of these phenotypes is incomplete. We have previously described more 161 
detailed clinico-pathologic classification of HIV-associated vasculopathy.[5] 162 
 163 
Here we report the clinical, laboratory, radiologic and autopsy features of HIV ischemic stroke 164 
patients, explore how they differ from the non-HIV ischemic stroke population, and consider the 165 
mechanisms of stroke among those starting antiretroviral therapy (ART). 166 
 167 
Methods 168 
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Participants 169 
The study was conducted at the Queen Elizabeth Central Hospital, Blantyre Malawi; a large 170 
government hospital for much of Southern Malawi. The national prevalence of HIV in adults is 10.6% 171 
but higher (20%) in Blantyre.[6] Adults (age >18 years) who presented to the hospital within seven 172 
days of symptom onset, and met the WHO case definition of stroke ‘a clinical syndrome consisting of 173 
rapidly developing clinical signs of focal (or global in case of coma) disturbance of cerebral function 174 
lasting more than 24 hours or leading to death with no apparent cause other than a vascular 175 
origin.',[7] were recruited to the study between February 2011 and April 2012 (Figure 1).  176 
 177 
Procedure and etiological definitions 178 
Clinical features, and potential vascular risk factors (i.e. age, gender, family history, ART use, 179 
hypertension, diabetes, hypercholesterolemia, acute infection, abdominal obesity, alcohol, smoking, 180 
substance use, and previous stroke/transient ischemic attack) were recorded. Stroke severity at 181 
baseline was assessed with the National Institutes of Health Stroke Scale (NIH stroke scale), and 182 
performed within 7 days of symptom onset.[8, 9] Evidence of peripheral vascular disease was 183 
determined by measuring ankle brachial index using a handheld vascular Doppler (HI Dop; Ana Wiz 184 
Ltd UK).[10] Magnetic Resonance Imaging (MRI) of the brain was performed within 7-days of 185 
admission. The definitions for risk factors, severity of stroke and imaging protocol were previously 186 
reported.[2] 187 
 188 
Investigations included full blood count, total cholesterol, random glucose, HIV-1 serology and viral 189 
load, CD4+ T-lymphocyte count (CD4+ count) using previously described methods.[2] HIV-1 RNA load 190 
was measured using the Hologic Aptima HIV-1 Quant Dx assay (Hologic Inc, Manchester, UK). This 191 
sensitive assay has a lower limit of quantitation (LLOQ) of 30 copies/ml and a limit of detection of 13 192 
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copies/ml.  .. Antiphospholipid syndrome diagnostics (anti-cardiolipin antibody, lupus anti-coagulant, 193 
anti-β2 –glycoprotein 1; Cambridge Life Sciences Ltd, Cambridgeshire, UK), and specific infection 194 
screening (1. serum syphilis treponemal immunoassay + agglutination test and non-treponemal 195 
tests, and if positive cerebrospinal fluid [CSF] venereal disease research laboratory test, and 2. 196 
monoclonal intrathecal varicella zoster[VZV]-antibody determination)[11] were not done locally and 197 
thus, performed using standard protocols, at the haematology department, Royal Liverpool Hospital 198 
UK, and Public Health England respectively. All blood cultures and CSF diagnostics [i.e. microscopy, 199 
biochemistry, India ink and acid fast bacilli stains, cryptococcal antigen, standard bacterial culture, 200 
Mycobacterium tuberculosis (TB) culture] were performed locally at the Malawi-Liverpool-Wellcome 201 
Trust (MLW) laboratory. MLW laboratory participates in internationally recognised quality control 202 
programmes including UK National External Quality Assessment Service and the South African 203 
National Health Laboratory Service scheme. Chest X-ray, electrocardiogram, carotid/vertebral duplex 204 
ultrasound and echocardiography were also performed. When possible, a brain-only autopsy was 205 
performed in deceased HIV positive patients. Brain tissue was stored in 10% formalin and processed 206 
at the University of Edinburgh, UK. The tissue sections were stained with hematoxylin and eosin and 207 
Ziehl-Neelsen stain. Additional staining included p24 antigen (for HIV) and CD8, CD68 and CD3 208 
antibodies (for inflammation). The results were interpreted by a neuropathologist and general 209 
pathologist with expertise in HIV infection. Although the pathologists were not blinded to the HIV 210 
status, a consensus had to be reached among these senior pathologists, with the third (HIV 211 
pathologist) arbitrating when needed. 212 
The etiology was determined using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 213 
classification (Figure 1). To expand the other determined and undetermined category and handle 214 
multiple etiologies in the HIV cohort, we also used the HIV Etiology for ischemic Stroke classification , 215 
as described previously (Figure 1). The physician that determined the final diagnosis was blinded to 216 
ART status, degree of immunosuppression and HIV viral burden.  217 
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 218 
Ethical consideration 219 
The study was approved by the Liverpool School of Tropical Medicine, UK and the College of 220 
Medicine Research Ethics Committee, University of Malawi. All participants or guardians gave 221 
written informed consent.  222 
 223 
Statistical analysis 224 
Discrete variables were reported as absolute counts and percentages. Continuous variables as the 225 
median with inter-quartile ranges. HIV viral load below the lower limit of quantitation were coded as 226 
30 copies/ml (the assays quantification limit).  This was then log transformed to compare the median 227 
HIV viral load across specified groups. Contingency tables comparing 1) HIV positive/negative, and 2) 228 
HIV etiology for stroke classification, were analyzed with Fisher’s two-sided exact test. Kruskal-Wallis 229 
non-parametric ANOVA was used to compare continuous variables.  230 
Statistical analyses were done with STATA 11.2. and GraphPad Prism version 6, GraphPad Software 231 
Inc., California, USA. A significance level of <0.05 was used throughout.  232 
 233 
  234 
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Results 235 
Three hundred patients with suspected stroke were screened during the study period, of whom 171 236 
(64 HIV positive and 107 HIV negative) had ischemic strokes and met the entry criteria (Figure 1). 237 
Table 1 describes the demographic and clinical characteristics of the HIV positive and negative 238 
individuals. The 64 HIV-infected ischemic stroke cases form the basis of this study.  Of these, 26 239 
(40%) were on ART and four had brain autopsy. 240 
 241 
Comparison between HIV positive and negative patients  242 
Compared with the HIV-negative patients, the HIV positive patients were significantly younger 243 
(median 40-years versus 66-years; p <0.001), and less likely to be hypertensive (42% versus 89%; 244 
p<0.001; Table 1). Other vascular risk factors including diabetes, hypercholesterolemia, and being a 245 
smoker, was more common in patients who were HIV negative. Imaging analysis showed that basal 246 
ganglia ischemia occurred more often with HIV ischemic stroke (68% versus 42%; p<0.001). Using the 247 
TOAST classification, the other determined and undetermined etiologic category were common in 248 
both groups.  However, for the better characterised categories, large artery disease had a different 249 
distribution and occurred more frequently in the HIV positive group (21% versus 10%; Table 1). 250 
 251 
Etiology of HIV-related ischemic stroke  252 
HIV-associated vasculopathy (i.e. accelerated atherosclerosis, non-atherosclerotic vasculopathy, HIV-253 
associated vasculitis and small vessel disease) was the commonest etiology (38%), followed by 254 
opportunistic infections (25%); the latter included VZV, TB, and syphilis (Table 2). Although VZV was 255 
the most frequent infection, it was often not clinically obvious with only 3/9 (30%) having had a 256 
vesicular rash in the corresponding cranial distribution within 6 months of their stroke. No patient 257 
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had evidence of occult cryptococcal disease. Despite a comprehensive work-up, a specific cause was 258 
not determined in the 17% with cryptogenic stroke.  259 
 260 
Age (p<0.001), CD4+ count (p=0.031), and ART status (p=0.048) differed significantly for the different 261 
etiologic groups. For example, non-atherosclerotic vasculopathy, HIV-associated vasculitis, 262 
opportunistic infection and cryptogenic stroke had a median age ≤45yrs (i.e. young stroke) whereas 263 
those with atherosclerotic vasculopathy and cardio-thromboembolism were older (Table 3). In the 264 
most immunosuppressed patients whose median CD4+ count was <200 cell/mm3, HIV-associated 265 
vasculitis, opportunistic infections and antiphospholipid syndrome were the most frequently found 266 
etiologies. The ART status differed significantly for these patients: 67% of those with HIV-associated 267 
vasculitis had started ART in the 6 months prior to their stroke; in contrast, only 33% of those with 268 
antiphospholipid syndrome, and 19% of those with opportunistic infections had recently started ART 269 
(Table 3). Furthermore, blood HIV viral load differed across these groups, being high (median 3.5 and 270 
4.7 copies/ml respectively) in patients with opportunistic infections and antiphospholipid syndrome, 271 
in contrast to being below the lower limit of quantitation, in patients with HIV-associated vasculitis. 272 
There were no significant differences in measured CSF cell count and biochemistry across the 273 
groups.  274 
 275 
HIV-associated vasculopathy 276 
The HIV-associated vasculopathy subtypes included accelerated atherosclerosis (n=7), non-277 
atherosclerosis (n=7) and HIV-associated vasculitis (n=9); the median age for these patients was 60-278 
years, 33-years and 35-years respectively (Table 3). Because there was only one case of small vessel 279 
disease, this was not included in the detailed analysis. The various types of HIV-associated 280 
vasculopathy differed by ART status and CD4+ count (Table 3); for example, no patient with 281 
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atherosclerotic vasculopathy had started ART in the last six months, compared with 43% of the non-282 
atherosclerotic and 67% of the HIV-associated vasculitis subtypes.  283 
 284 
At autopsy (Supplement Figure 1), two patients showed extensive atherosclerosis in all sized vessels 285 
(the images were consistent), one was on ART and young (50-years), with no established vascular 286 
risk factors. Although the other patient was older (74-years), not on ART, with a new diagnosis of 287 
hypertension; the degree of atherosclerosis was marked.  All patients with HIV-associated vasculitis 288 
had a median CD4+ count of <200cells/mm3, and HIV-1 RNA were below the lower limit of 289 
quantitation ; this differed from those with non-atherosclerotic and atherosclerotic vasculopathy 290 
(Table 3).  291 
 292 
Initiating ART 293 
Sixteen out of 64 (25%) patients had an ischemic stroke within 6 months of starting ART. Ten (63%) 294 
of these recent ART-initiators had a stroke within 1 month of starting ART. The median age, CD4+ 295 
count and blood HIV viral load were 37-years (IQR:31,47), 122 cells/mm3 (IQR:73,237) and 1.5 log10 296 
copies/ml (IQR:0.7,2.1) respectively. We explored established risk factors for immune reconstitution 297 
inflammatory syndrome (IRIS), such as anemia, low CD4+ count, and a drop in HIV viral load. Patients 298 
recently started on ART had the lowest median CD4+ count (122 [IQR: 73,236] compared to 159 299 
[IQR: 65,279] in patients never started on ART, and 295 [IQR: 192,455] in patients on ART for ≥6 300 
months (p=0.107). Recent ART-initiators were also more anemic (median haemoglobin 11.0 g/dl 301 
[IQR:9.0,12.0]) and had lower viral loads than the other ART categories (Figure 2). The distribution of 302 
etiologies differed substantially by ART status group (P <0.048; Figure 1), in keeping with the 303 
epidemiologic evidence that the first 6 months of ART is a high risk period for stroke.[2] Within this 304 
time period, HIV-associated vasculopathy (specifically the HIV-associated vasculitis [n=6] and non-305 
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atherosclerotic vaculopathy [n=3]) was the commonest diagnosis (56 %). Brain histologic material 306 
from two IRIS-like cases revealed TB Meningitis and HIV-associated vasculitis (Figure 3).  307 
 308 
Discussion 309 
This in-depth analysis of a large cohort of patients shows that ischemic stroke in people with HIV 310 
infection is distinct from the non-HIV population, with a younger age of onset and a different risk 311 
factor profile.  Based on clinical, radiologic and autopsy analysis, we found that HIV-associated 312 
vasculopathy and opportunistic infections were the most common etiologies. Among patients with 313 
HIV-associated vasculopathy, the three subtypes (i.e. accelerated atherosclerosis, non-314 
atherosclerosis and vasculitis) appear to have different risk factors. Importantly, most ischemic 315 
stroke patients with non-atherosclerotic vasculopathy or HIV-associated vasculitis had recently 316 
started on ART, which is suggestive of IRIS.  317 
 318 
IRIS occurs during immune system recovery after an immune deficient state. It is associated with a 319 
rapid decline (of 2 logs or more) in HIV viral load, a low nadir and then rising CD4+ count following 320 
ART introduction, and anemia.[12] [13-15] The mechanism, although widely believed to be driven by 321 
infiltration of active T-cells, still remains unclear.[14]  In our cohort, those presenting with a stroke 322 
after recently starting ART showed some risk factors for IRIS.[16] However, although HIV viral loads 323 
appeared to be largely supressed, we did not see the higher CD4+ counts and therefore evidence of 324 
immune reconstitution typically associated with IRIS. This immune-virologic discordance was 325 
unexpected and suggests persistent immune dysregulation. Arguably, cell counts may not wholly 326 
reflect function and as evidenced by viral suppression, there may have been immune recovery even 327 
in the absence of an increased CD4+ count.[15] Such immune-virologic discordance was recently 328 
implicated in non-AIDS complications, and thus this merits further investigation.[17]  329 
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  330 
Patients diagnosed with HIV-associated vasculitis were highly immunosuppressed and thus it is 331 
plausible that vessel wall inflammation was driven by an undiagnosed opportunistic infection. 332 
Tuberculosis and cryptococcus, for example, are frequent triggers of central-nervous system (CNS)-333 
IRIS.[18] However, patients with confirmed opportunistic infections tended not to be on ART, and 334 
had a correspondingly high HIV viral load. Furthermore, TB was only identified in 6% of ischemic 335 
stroke and we did not detect cryptococcal disease. Of our 4 patients who had autopsy following 336 
ischemic stroke, one patient with characteristic features of endarteritis obliterans was diagnosed 337 
clinically and confirmed at autopsy with TB meningitis.  Nonetheless,  our results are more consistent 338 
with CNS-IRIS triggered by an immune response to HIV viral antigens per se. [14] The postulated 339 
mechanisms include immune response directed at residual HIV virus in the CNS, persistent release of 340 
HIV-Tat protein from HIV-infected cells despite control of viral replication, and inflammatory 341 
responses directed against self-antigens.[14]  342 
 343 
Patients with atherosclerotic vasculopathy were not as immunosuppressed as patients with other 344 
subtypes of HIV-associated vasculopathy. The relatively young patient ID:218, who was on ART for > 345 
6 months, showed histologic evidence of extensive atherosclerosis in the absence of other vascular 346 
risk factors (Supplement Figure 1). At a population level, studies in high income countries have 347 
consistently shown that HIV-positive individuals have a substantially high risk of stroke, roughly 348 
equivalent to that of general population cohorts 10-20 years older than themselves.[19] This is 349 
despite exposure to opportunistic infections being far lower, and the additive risk of ART toxicity and 350 
HIV/ART induced metabolic dysregulation (e.g. hyperlipidaemia) being accounted for.[4, 19]  HIV 351 
could have a causal role in this disease mechanism but this is still open to debate. However, there is 352 
growing evidence that HIV-related chronic inflammation even in well-suppressed HIV infected 353 
individuals is linked to sub-clinical vasculopathy.[4] Whilst HIV-associated vasculopathy appears to 354 
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be more common in Sub-Saharan Africa compared with elsewhere, the atherosclerotic and 355 
cryptogenic subtypes are likely to become the predominant subtypes as the HIV population ages and 356 
the disease stabilizes, and thus, warrants further investigation. 357 
 358 
There were some limitations to the study, for example, we did not screen for sickle cell disease. 359 
However, although commonly associated with stroke elsewhere in sub-Saharan Africa, the 360 
prevalence of sickle cell disease in Malawi is low (<2%) and thus unlikely to have made a major 361 
contribution.[20] The absence of cerebral angiography limited our ability to refine the diagnosis of 362 
the cryptogenic group and thus further subdivide them into cardiac embolic or non-cardiac embolic 363 
causes. Indeed the latter could have represented undiagnosed HIV-associated vasculopathy. 364 
Furthermore, non-atherosclerotic vasculopathy and HIV-associated vasculitis could be 365 
manifestations of the same disease process at different stages of HIV infection, It is possible that the 366 
hospital recruitment may have been biased against milder cases in the community. It is also possible 367 
that the risk of stroke seen in those starting ART may be related to being sick and not ART itself, 368 
although difficult to tease out, our proposed mechanism of IRIS is not dissimilar to other infections, 369 
in the very immunosuppressed, such as TB and Cryptococcus CNS infection.[15, 21] Finally, CNS IRIS 370 
is associated with a poor prognosis and often fatal within days-weeks if untreated, leaving the 371 
possibility that ischemic stroke among those starting ART could have been underestimated if 372 
patients died before hospital admission.[14, 18]   373 
 374 
HIV-associated vasculopathy and opportunistic infections are common causes of HIV-related 375 
ischemic stroke. Furthermore, subtypes of HIV-associated vasculopathy may manifest as a result of 376 
an immune reconstitution-like syndrome after starting ART.  This study highlights the different 377 
phenotypes of HIV-associated vasculopathy and ties in with emerging data on neuro-inflammation 378 
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pre- and post HIV-infection. Our understanding of the underlying mechanism and the role that HIV 379 
plays is incomplete, especially on better treated cohorts with cryptogenic stroke, and possibly ‘HIV-380 
associated’ atherosclerosis. This highlights the importance for future mechanistic studies to 381 
underpin the pathogenesis of these various subtypes and in time, pave the way for appropriate 382 
interventions. 383 
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Figure 1: Selection procedure and classification of cases 468 
Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory of 469 
‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined 470 
 471 
Figure 2: Clinical, radiologic and laboratory features among those starting ART  472 
(A) Etiology by ART status shows HIV-associated vasculopathy to be the most common etiology among those starting ART. 473 
(B) Radiologic examples of HIV-associated vasculopathy found among those starting ART: ID 32: Diffusion weighted ) [left] 474 
and Fluid Attenuated Inversion Recovery (FLAIR) [middle] sequences show a left Middle cerebral artery  infarct, while 475 
Doppler of the left common carotid artery [right] illustrates underlying concentric stenosis (≥70%) extending into the bulb.; 476 
ID 278 – Middle cerebral artery  infarct on Diffusion weighted [left] and T2-weighted [right] sequences; ID 46 and 85 - 477 
Diffusion weighted and FLAIR sequences show multifocal ischemic lesions in the basal ganglia and cortices. (C) Risk factors 478 
of immune reconstitution syndrome compared across the ART groups. Kruskal-Wallis non-parametric ANOVA was used to 479 
compare continuous variables across the ART treatment status groups. 480 
ART – antiretroviral treatment, CD4+ count – CD4+ T-lymphocyte count, IRIS – Immune Reconstitution Inflammatory 481 
Syndrome, CTE – Cardio-thromboembolism, O.I – Opportunistic infections, APS – Anti-phospholipid syndrome, 482 
Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory of 483 
‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined. 484 
 485 
Figure 3: Radio-histologic characteristics in patients presenting with HIV-associated vasculitis 486 
versus vasculitis related to TB meningitis after starting ART 487 
 488 
1.a-e;A 32 year old (5 months pregnant) female on ART for less than 6 months with an acute right arm monoparesis , 489 
dysphasia and headache. Her CD4+ count was 175cells/mm3 and HIV blood and CSF viral load were undetected on 490 
admission. Mild pleocytosis (White cell count 10 cells/mm3), moderately elevated protein (1.6mg/L) and a glucose ratio of 491 
0.48 was found on CSF examination. MRI 1.a-1.c confirmed an acute middle cerebral artery infarct. Histopathology (1.d-e) 492 
Multiple infarction of the cortical laminar type, marked periarteritis with foci of muscle necrosis, present in all sized 493 
arteries. There was lymphocytic meningitis but no granuloma or caseation or giant cells typical of TB meningitis. There was 494 
no CMV inclusion bodies and varicella zoster intrathecal IgG was negative. 2.a-e; A 34 year old female on ART for less than 495 
6 months with an acute right arm weakness, headache, neck ache and fever. CD4+ count was 128 cells/mm3 and HIV blood 496 
and CSF viral load on admission were 1.48 and 3.22 log10 copies/ml respectively. There was no CSF pleocytosis but a 497 
markedly elevated protein of 16.6mg/L and CSF glucose ratio of 0.28. MRI brain confirmed an acute infarct of the basal 498 
ganglia with mild hydrocephalus. Histopathology (2.d-e) Endarteritis obliterans of the small arteries with and a recent 499 
infarct of the basal ganglia.  There was widespread meningeal inflammation with confluent and discrete tuberculoid 500 
granulomas, typical caseating necrosis and Langhans’ giant cells. There were superficial Rich foci (i.e. tuberculous cerebritis 501 
adjacent to the meninges). Acid fast bacilli stain was negative but histology was characteristic of TB meningitis 502 
 503 
Supplement Figure 1: Histologic illustration of atherosclerotic vasculopathy: 504 
 505 
A 50 year old man on ART for greater than 6 months with an acute left hemiparesis. His CD4+ count was 192 cells/mm3 and 506 
HIV blood and CSF viral load were undetected on admission. He had no pleocytosis, a mildly elevated protein (0.9 mg/L) 507 
and a glucose ratio of 0.48 on CSF examination. A comprehensive etiological screen was unremarkable. Histopathology 508 
showed an acute infarct in the right cerebral hemisphere, and extensive atherosclerosis in all sized vessels, in both the left 509 
and right cerebral hemispheres. Sections of the right carotid artery had substantial atheroma. There was no acute 510 
thrombus. There was no HIV-associated encephalitis. 511 
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512 
Table 1: Clinical, and radiologic characteristics of ischemic stroke in HIV positive and negative 
cohorts 
 HIV positive (n=64) HIV negative 
(n=107) 
P value¥ 
Median Age (IQR) 40 (32,51) 66 (53,77) <0.001 
Male sex (%) 29 (45) 49 (46) 1.000 
Family history 9 (14) 17 (17) 0.403 
Hypertension (%) 27 (42) 89 (83) <0.001 
Diabetes (%) 2 (3) 14 (13) 0.032 
Hypercholesterolemia (%) 4 (7) 10 (10) 0.510 
Current smoker (%) 6 (9) 26 (24) 0.016 
Recent infection (%) 12 (19) 8 (8) 0.082 
ETOH intake (%) 13 (21) 14 (13) 0.379 
Cannabis use (%) 1 (2) 3 (3) 1.000 
Obesity (%) 
 T1 
 T2 
 T3 
 
14 (22) 
23 (37) 
26 (41) 
 
17 (16) 
33 (31) 
56 (53) 
 
0.496 
Median ankle brachial index 1.01 (0.96,1.01) 1.01 (0.94,1.06) 0.946 
Previous TIA 4 (6) 7 (7) 0.274 
Previous Stroke 4 (6) 15 (14) 0.244 
Radiologic Characteristics    
Acute/ subacute MRI lesions 
Cerebral cortex 
Cerebellum 
Brainstem 
Basal ganglia 
Periventricular white matter disease 
Other*** 
More than one focal lesion (%) 
 
39 (68) 
4 (7) 
6 (11) 
39 (68) 
24 (42) 
1 (2) 
12 (21) 
 
61 (66) 
3 (3) 
9 (10) 
39 (42) 
33 (36) 
2 (2) 
6 (8) 
 
0.721 
0.297 
0.866 
0.002 
0.418 
0.162 
0.034 
Stroke characteristics  
 Median NIH stroke scale  12 (8,14) 11 (7,18) 0.813 
Etiology of Stroke (TOAST) 
 Large artery disease 
 Cardio-thromboembolism 
 Small vessel disease 
 Stroke of other determined∞ 
 Stroke of undetermined 
 
14 (21) 
4 (6) 
1 (1) 
31 (46) 
18 (27) 
 
14 (10) 
13 (9) 
 3 (2) 
15 (11) 
92 (67) 
 
 
 
<0.001 
Hospital Fatality 11 (17) 10 (9) 0.152 
** Cerebral cortex includes frontal, temporal, occipital and parietal lobe 
***Corpus callosum, hypothalamus, pituitary, cranio-cervical junction 
¥ Categorical variables were analyzed with Fisher’s two-sided exact test. Kruskal-Wallis non-parametric ANOVA was used to 
compare continuous variables 
∞Stroke of Other determined cause in the HIV negative group includes; 7 – Probable antiphospholipid syndrome, 4- 
Syphilis, 2 –Varicella zoster, 1 – TB, 1- Probable vasculitis.  
†See Table 3 for HIV-associated stroke 
T=Tertile 
cp/ml=copies/ml 
Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory 
of ‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined. 
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Table 2: Clinical features of the different etiologies found in HIV-related ischemic stroke† 
 HIV-associated vasculopathy¤ 
N=23 
Opportunistic 
Infections 
N=16 
 
 
Anti-phospholipid 
syndrome 
N=6 
Cardio-thrombo 
embolism 
N=4 
Cryptogenic* 
stroke n=11 
P value¥ 
Atherosclerotic 
vasculopathy 
(n=7) 
Non-
atherosclerotic 
vasculopathy 
(n=7) 
 HIV-associated 
vasculitis 
(n=9) 
Median age (IQR) 60 (50,68) 33 (24,42) 35 (32,42) 35 (28,41) 42 (32,52) 58 (48,69) 44 (31,54) <0.001 
Male (%) 4 (57) 4 (57) 4 (44) 5 (31) 4 (67) 2 (50) 2 (50) 0.606 
ART status (%) 
 Untreated 
 <6 months on treatment 
 ≥6 months on treatment 
 
4 (57) 
0  
3 (43) 
 
4 (57) 
3 (43) 
0 
 
2 (22) 
6 (67) 
1 (11) 
 
12 (75) 
3 (19) 
1 (6) 
 
4 (67) 
2 (33) 
0 
 
2 (50) 
1 (25) 
1 (25) 
 
7 (64) 
1 (9) 
3 (27) 
 
0.048 
CD4+ T-lymphocyte count mm3 271 (192,318) 248 (218,305) 88 (15,117) 131 (61,294) 93 (63,159) 302 (240,558) 204 (51,458) 0.031 
HIV blood viral load log10 cp/ml 3.1 (0,4.4) 3.7 (1.5,4.3) 0 (0,2.5) 3.5 (2.4,4.6) 4.7 (2.0,5.3) 1.5 (0,4.0) 1.5 (0,4.6) 0.183 
Haemoglobin (g/dl) 12.0 (9.0,15.0) 11.0 (9.0,15.0) 12.0 (10.0,14.0) 12.0 (10.0,13.0) 10.0 (9.0,12.0) 14.0 (13.0,15.0) 12.0 (9.0,13.0) 0.720 
 
NIH stroke scale  
 
12 (7,14) 
 
11(8,17) 
 
13(12,18) 
 
13 (8,16) 
 
10 (7,12) 
 
9 (8,11) 
 
11 (6,14) 
 
0.596 
Hospital fatality 2 (29) 1 (14) 2 (22) 3 (19) 1 (17) 0 2 (18) 0.955 
†Continuous variable presented as median with interquartile ranges 
¤ Small vessel disease (n=1), Multifactorial stroke (n=1) and Inconclusive (n=2) were not included in the analysis. 
¥ Categorical variables were analyzed with Fisher’s two-sided exact test. Kruskal-Wallis non-parametric ANOVA was used to compare continuous variables 
ART – antiretroviral treatment  
Cryptogenic* - * indicates that non-invasive or invasive angiography was not done and therefore the subcategory of ‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined 
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Abstract 142 
  143 
Background: HIV infection is a recognized risk factor for young stroke but the exact mechanisms are 144 
poorly understood. We studied the clinical, radiologic and histologic features of HIV-related ischemic 145 
stroke to gain insight into the disease mechanisms. 146 
Methods: We conducted a prospective, in-depth analysis of adult ischemic stroke patients 147 
presenting to Queen Elizabeth Central Hospital, Blantyre, Malawi, in 2011.  148 
Results: We recruited 64 HIV positive and 107 HIV negative patients. Those with HIV were 149 
significantly younger (p<0.001) and less likely to have established vascular risk factors. Patients with 150 
HIV were more likely to have large artery disease (21% versus 10%; p <0.001). The commonest 151 
etiology was HIV-associated vasculopathy (24 [38%]), followed by opportunistic infections (16[25%]). 152 
Sixteen out of 64 (25%) had a stroke soon after starting antiretroviral therapy (ART), suggesting an 153 
immune reconstitution-like syndrome. In this group CD4+ T-lymphocyte count was low, despite a 154 
significantly lower HIV viral load in those recently started on treatment (p<0.001).  155 
Conclusions: HIV-associated vasculopathy and opportunistic infections are common causes of HIV-156 
related ischemic stroke. Furthermore, subtypes of HIV-associated vasculopathy may manifest as a 157 
result of an immune reconstitution-like syndrome after starting ART.  A better understanding of this 158 
mechanism may point towards new treatments. 159 
 160 
Key words:  Stroke, Vasculopathy, HIV, Africa, Immune reconstitution syndrome  161 
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Introduction  162 
Stroke incidence in low-to-middle income countries is increasing, especially in young populations.[1] 163 
In many of these regions, HIV is prevalent, and younger populations are more likely to have 164 
infectious causes of stroke.[2] 165 
We recently showed that HIV infection makes a major contribution to the overall stroke burden 166 
(Population Attributable [PAF] Fraction 15%) in Malawi.[2] It was the second leading risk factor 167 
overall (behind hypertension), and the most important among young stroke patients (Population 168 
Attributable FractionPAF 42%). Starting antiretroviral (ART) treatment appeared to contribute to 169 
stroke risk in the very immunosuppressed, but the mechanism of this is unknown.[2] Previous 170 
reports have shown that opportunistic infections, coagulopathy and cardio-thromboembolism are 171 
important etiologies to consider.[3] In addition, HIV infection may directly lead to HIV-associated 172 
vasculopathy via inflammatory intermediaries.[4] The term vasculopathy is defined as intimal hyperplasia 173 
more than expected for age, and thus encompasses several pathologic phenotypes of stroke found in HIV 174 
infection including, 1) HIV associated accelerated atherosclerosis, 2) non-atherosclerotic vasculopathy 175 
(patients have non-vasculitic abnormalities, with intimal hyperplasia that can progress to stenosis or 176 
aneurysmal dilatation) 3) HIV-associated vasculitis, and 4) small vessel disease.[5] Our understanding 177 
of the pathologic mechanisms of these phenotypes is incomplete. We have previously described more 178 
detailed clinico-pathologic classification of HIV-associated vasculopathy.[5] 179 
 180 
Here we report the clinical, laboratory, radiologic and autopsy features of HIV ischemic stroke 181 
patients, explore how they differ from the non-HIV ischemic stroke population, and consider the 182 
mechanisms of stroke among those starting antiretroviral therapy (ART). 183 
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 184 
Methods 185 
Participants 186 
The study was conducted at the Queen Elizabeth Central Hospital, Blantyre Malawi; a large 187 
government hospital for much of Southern Malawi. The national prevalence of HIV in adults is 10.6% 188 
but higher (20%) in Blantyre.[6] Adults (age >18 years) who presented to the hospital within seven 189 
days of symptom onset, and met the WHO case definition of stroke ‘a clinical syndrome consisting of 190 
rapidly developing clinical signs of focal (or global in case of coma) disturbance of cerebral function 191 
lasting more than 24 hours or leading to death with no apparent cause other than a vascular 192 
origin.',[7] were recruited to the study between February 2011 and April 2012 (Figure 1).  193 
 194 
Procedure and etiological definitions 195 
Baseline clinical assessment has been described elsewhere.[2] Clinical features, and potential 196 
vascular risk factors (i.e. age, gender, family history, ART use, hypertension, diabetes, 197 
hypercholesterolemia, acute infection, abdominal obesity, alcohol, smoking, substance use, 198 
previousand previous stroke/transient ischemic attack) were recorded. Stroke severity at baseline 199 
was assessed with the National Institutes of Health Stroke Scale (NIH stroke scaleNIHSS), and 200 
performed within 7 days of symptom onset.[8, 9] Evidence of peripheral vascular disease was 201 
determined by measuring ankle brachial index using a handheld vascular Doppler (HI Dop; Ana Wiz 202 
Ltd UK).[10] Magnetic Resonance Imaging (MRI) of the brain was performed within 7-days of 203 
admission. The definitions for risk factors, severity of stroke and imaging protocol were previously 204 
reported.[2] 205 
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 206 
Investigations included full blood count, total cholesterol, random glucose, HIV-1 serology and viral 207 
load, CD4+ T-lymphocyte count (CD4+ count) using previously described methods.[2] HIV-1 RNA load 208 
was measured using the Hologic Aptima HIV-1 Quant Dx assay (Hologic Inc, Manchester, UK). This 209 
sensitive assay has a lower limit of quantitation (LLOQ) of 30 copies/ml and a limit of detection of 13 210 
copies/ml.  .Undetectable The limit of detection for HIV viral load was defined as ≤1.5 log1050 211 
copies/ml (Hologic Commercial kits, Sussex, UK). Antiphospholipid syndrome diagnostics (anti-212 
cardiolipin antibody, lupus anti-coagulant, anti-β2 –glycoprotein 1; Cambridge Life Sciences Ltd, 213 
Cambridgeshire, UK), and specific infection screening (1. serum syphilis treponemal immunoassay + 214 
agglutination test and non-treponemal tests, and if positive cerebrospinal fluid [CSF] venereal 215 
disease research laboratory test, and 2. monoclonal intrathecal varicella zoster[VZV]-antibody 216 
determination)[11] were not done locally and thus, performed using standard protocols, at the 217 
haematology department, Royal Liverpool Hospital UK, and Public Health England respectively. All 218 
blood cultures and CSF diagnostics [i.e. microscopy, biochemistry, India ink and acid fast bacilli 219 
stains, cryptococcal antigen, standard bacterial culture, Mycobacterium tuberculosis (TB) culture] 220 
were performed locally at the Malawi-Liverpool-Wellcome Trust (MLW) laboratory. MLW laboratory 221 
participates in internationally recognised quality control programmes including NEQAS (UK National 222 
External Quality Assessment Service) and the South African National Health Laboratory Service NHLS 223 
scheme. Chest X-ray, electrocardiogram, carotid/vertebral duplex ultrasound and echocardiography 224 
were also performed. When possible, a brain-only autopsy was performed in deceased HIV positive 225 
patients. Brain tissue was stored in 10% formalin and processed at the University of Edinburgh, UK. 226 
The tissue sections were stained with hematoxylin and eosin and Ziehl-Neelsen stain. Additional 227 
staining included p24 antigen (for HIV) and CD8, CD68 and CD3 antibodies (for inflammation). The 228 
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results were interpreted by a neuropathologist and general pathologist with expertise in HIV 229 
infection. Although the pathologists were not blinded to the HIV status, a consensus had to be 230 
reached among these senior pathologists, with the third (HIV pathologist) arbitrating when needed. 231 
 232 
 233 
The etiology was determined using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 234 
classification (Figure 1). To expand the other determined and undetermined category and handle 235 
multiple etiologies in the HIV cohort, we also used the HIV Etiology for ischemic Stroke classification 236 
(HES), as described previously (Figure 1). The physician that determined the final diagnosis was 237 
blinded to ART status, degree of immunosuppression and HIV viral burden.  238 
 239 
 240 
Ethical consideration 241 
The study was approved by the Liverpool School of Tropical Medicine, UK and the College of 242 
Medicine Research Ethics Committee, University of Malawi. All participants or guardians gave 243 
written informed consent.  244 
 245 
 246 
Statistical analysis 247 
Discrete variables were reported as absolute counts and percentages. Continuous variables as the 248 
median with inter-quartile ranges. HIV viral load below the lower limit of quantitation detection limit 249 
were coded as 530 copies/ml (the assays detectionquantification limit).  This was then log 250 
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transformed to compare the median HIV viral load across specified groups.  Contingency tables 251 
comparing 1) HIV positive/negative, and 2) HIV etiology for stroke classification, were analyzed with 252 
Fisher’s two-sided exact test. Kruskal-Wallis non-parametric ANOVA was used to compare 253 
continuous variables.  254 
Statistical analyses were done with STATA 11.2. and GraphPad Prism version 6, GraphPad Software 255 
Inc., California, USA. A significance level of <0.05 was used throughout.  256 
 257 
  258 
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Results 259 
Three hundred patients with suspected stroke were screened during the study period, of whom 171 260 
(64 HIV positive and 107 HIV negative) had ischemic strokes and met the entry criteria (Figure 1). 261 
Table 1 describes the demographic and clinical characteristics of the HIV positive and negative 262 
individuals. The 64 HIV-infected ischemic stroke cases form the basis of this study.  Of these, 26 263 
(40%) were on ART and four had brain autopsy. 264 
 265 
  266 
 267 
  268 
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Comparison between HIV positive and negative patients  269 
Compared with the HIV-negative patients, the HIV positive patients were significantly younger 270 
(median 40-years versus 66-years; p <0.001), and less likely to be hypertensive (42% versus 89%; 271 
p<0.001; Table 1). Other vascular risk factors including diabetes, hypercholesterolemia, and being a 272 
smoker, was more common in patients who were HIV negative. Imaging analysis showed that basal 273 
ganglia ischemia occurred more often with HIV ischemic stroke (68% versus 42%; p<0.001). Using the 274 
TOAST classification, the other determined and undetermined etiologic category were common in 275 
both groups.  However, for the better characterised categories, large artery disease had a different 276 
distribution and occurred more frequently in the HIV positive group (21% versus 10%; Table 1). 277 
 278 
Etiology of HIV-related ischemic stroke  279 
HIV-associated vasculopathy (i.e. accelerated atherosclerosis, non-atherosclerotic vasculopathy, HIV-280 
associated vasculitis and small vessel disease) was the commonest etiology (38%), followed by 281 
opportunistic infections (25%); the latter included VZV, TB, and syphilis (Table 2). Although VZV was 282 
the most frequent infection, it was often not clinically obvious with only 3/9 (30%) having had a 283 
vesicular rash in the corresponding cranial distribution within 6 months of their stroke. No patient 284 
had evidence of occult cryptococcal disease. Despite a comprehensive work-up, a specific cause was 285 
not determined in the 17% with cryptogenic stroke.  286 
 287 
Age (p<0.001), CD4+ count (p=0.031), and ART status (p=0.048) differed significantly for the different 288 
etiologic groups. For example, non-atherosclerotic vasculopathy, HIV-associated vasculitis, 289 
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opportunistic infection and cryptogenic stroke had a median age ≤45yrs (i.e. young stroke) whereas 290 
those with atherosclerotic vasculopathy and cardio-thromboembolism were older (Table 3). In the 291 
most immunosuppressed patients whose median CD4+ count was <200 cell/mm3, HIV-associated 292 
vasculitis, opportunistic infections and antiphospholipid syndrome were the most frequently found 293 
etiologies. The ART status differed significantly for these patients: 67% of those with HIV-associated 294 
vasculitis had started ART in the 6 months prior to their stroke; in contrast, only 33% of those with 295 
antiphospholipid syndrome, and 19% of those with opportunistic infections had recently started ART 296 
(Table 3). Furthermore, blood HIV viral load differed across these groups, being high (median 3.5 and 297 
4.7 copies/ml respectively) in patients with opportunistic infections and antiphospholipid syndrome, 298 
in contrast to being below the lower limit of quantitationbeing below the limit of detection, 299 
undetectable viral load in patients with HIV-associated vasculitis. There were no significant 300 
differences in measured CSF cell count and biochemistry across the groups.  301 
 302 
 303 
HIV-associated vasculopathy 304 
The HIV-associated vasculopathy subtypes included accelerated atherosclerosis (n=7), non-305 
atherosclerosis (n=7) and HIV-associated vasculitis (n=9); the median age for these patients was 60-306 
years, 33-years and 35-years respectively (Table 3). Because there was only one case of small vessel 307 
disease, this was not included in the detailed analysis. The various types of HIV-associated 308 
vasculopathy differed by ART status and CD4+ count (Table 3); for example, no patient with 309 
atherosclerotic vasculopathy had started ART in the last six months, compared with 43% of the non-310 
atherosclerotic and 67% of the HIV-associated vasculitis subtypes.  311 
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 312 
At autopsy (Supplement Figure 1), two patients showed extensive atherosclerosis in all sized vessels 313 
(the images were consistent), one was on ART and young (50-years), with no established vascular 314 
risk factors. Although the other patient was older (74-years), not on ART, with a new diagnosis of 315 
hypertension; the degree of atherosclerosis was marked.  All patients with HIV-associated vasculitis 316 
had a median CD4+ count of <200cells/mm3, and HIV-1 RNA were below the lower limit of 317 
quantitation below the limit of detection undetectable or lowfor HIV viral load; this differed from 318 
those with non-atherosclerotic and atherosclerotic vasculopathy (Table 3).  319 
 320 
 321 
 322 
Initiating ART 323 
Sixteen out of 64 (25%) patients had an ischemic stroke within 6 months of starting ART. Ten (63%) 324 
of these recent ART-initiators had a stroke within 1 month of starting ART. The median age, CD4+ 325 
count and blood HIV viral load were 37-years (IQR:31,47), 122 cells/mm3 (IQR:73,237) and 1.5 log10 326 
copies/ml (IQR:0.7,2.1) respectively. We explored established risk factors for immune reconstitution 327 
inflammatory syndrome (IRIS), such as anemia, low CD4+ count, and a drop in HIV viral load. Patients 328 
recently started on ART had the lowest median CD4+ count (122 [IQR: 73,236] compared to 159 329 
[IQR: 65,279] in patients never started on ART, and 295 [IQR: 192,455] in patients on ART for ≥6 330 
months (p=0.107). Recent ART-initiators were also more anemic (median haemoglobin 11.0 g/dl 331 
[IQR:9.0,12.0]) and had lower viral loads than the other ART categories (Figure 2). The distribution of 332 
etiologies differed substantially by ART status group (P <0.048; Figure 1), in keeping with the 333 
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epidemiologic evidence that the first 6 months of ART is a high risk period for stroke.[2] Within this 334 
time period, HIV-associated vasculopathy (specifically the HIV-associated vasculitis [n=6] and non-335 
atherosclerotic vaculopathy [n=3]) was the commonest diagnosis (56 %). Brain histologic material 336 
from two IRIS-like cases revealed TB Meningitis and HIV-associated vasculitis (Figure 3).  337 
 338 
Discussion 339 
This in-depth analysis of a large cohort of patients shows that ischemic stroke in people with HIV 340 
infection is distinct from the non-HIV population, with a younger age of onset and a different risk 341 
factor profile.  Based on clinical, radiologic and autopsy analysis, we found that HIV-associated 342 
vasculopathy and opportunistic infections were the most common etiologies. Among patients with 343 
HIV-associated vasculopathy, the three subtypes (i.e. accelerated atherosclerosis, non-344 
atherosclerosis and vasculitis) appear to have different risk factors. Importantly, most ischemic 345 
stroke patients with non-atherosclerotic vasculopathy or HIV-associated vasculitis had recently 346 
started on ART, which is suggestive of IRIS.  347 
 348 
IRIS occurs during immune system recovery after an immune deficient state. It is associated with a 349 
rapid decline (of 2 logs or more) in HIV viral load, a low nadir and then rising CD4+ count following 350 
ART introduction, and anemia.[12] [13-15] The mechanism, although widely believed to be driven by 351 
infiltration of active T-cells, still remains unclear.[14]  In our cohort, those presenting with a stroke 352 
after recently starting ART showed some risk factors for IRIS.[16] However, although HIV viral loads 353 
appeared to be largely supressed, we did not see the higher CD4+ counts and therefore evidence of 354 
immune reconstitution typically associated with IRIS. This immune-virologic discordance was 355 
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unexpected and suggests persistent immune dysregulation. Arguably, cell counts may not wholly 356 
reflect function and as evidenced by viral suppression, there may have been immune recovery even 357 
in the absence of an increased CD4+ count.[15] Such immune-virologic discordance was recently 358 
implicated in non-AIDS complications, and thus this merits further investigation.[17]  359 
  360 
Patients diagnosed with HIV-associated vasculitis were highly immunosuppressed and thus it is 361 
plausible that vessel wall inflammation was driven by an undiagnosed opportunistic infection. 362 
Tuberculosis and cryptococcus, for example, are frequent triggers of central-nervous system (CNS)-363 
IRIS.[18] However, patients with confirmed opportunistic infections tended not to be on ART, and 364 
had a correspondingly high HIV viral load. Furthermore, TB was only identified in 6% of ischemic 365 
stroke and we did not detect cryptococcal disease. Of our 4 patients who had autopsy following 366 
ischemic stroke, one patient with characteristic features of endarteritis obliterans was diagnosed 367 
clinically and confirmed at autopsy with TB meningitisTBM.  Nonetheless,  our results are more 368 
consistent with CNS-IRIS triggered by an immune response to HIV viral antigens per se. [14] The 369 
postulated mechanisms include immune response directed at residual HIV virus in the CNS, 370 
persistent release of HIV-Tat protein from HIV-infected cells despite control of viral replication, and 371 
inflammatory responses directed against self-antigens.[14]  372 
 373 
 374 
Patients with atherosclerotic vasculopathy were not as immunosuppressed as patients with other 375 
subtypes of HIV-associated vasculopathy. The relatively young patient ID:218, who was on ART for > 376 
6 months, showed histologic evidence of extensive atherosclerosis in the absence of other vascular 377 
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risk factors (Supplement Figure 1). At a population level, studies in high income countries have 378 
consistently shown that HIV-positive individuals have a substantially high risk of stroke, roughly 379 
equivalent to that of general population cohorts 10-20 years older than themselves.[19] This is 380 
despite exposure to opportunistic infections being far lower, and the additive risk of ART toxicity and 381 
HIV/ART induced metabolic dysregulation (e.g. hyperlipidaemia) being accounted for.[4, 19]  HIV 382 
could have a causal role in this disease mechanism but this is still open to debate. However, there is 383 
growing evidence that HIV-related chronic inflammation even in well-suppressed HIV infected 384 
individuals is linked to sub-clinical vasculopathyWhether HIV has a causal role is still open to debate 385 
however, Tthere is growing evidence that the HIV-related chronic inflammation that accompanies 386 
even in well-suppressed HIV infected individualsinfection, may play a critical an important role in 387 
thise mechanism.[4] Whilst HIV-associated vasculopathy appears to be more common in Sub-388 
Saharan Africa compared with elsewhere, the atherosclerotic and cryptogenic subtypes are likely to 389 
become the predominant subtypes as the HIV population ages and the disease stabilizes, and thus, 390 
warrants further investigation. 391 
 392 
There were some limitations to the study, for example, we did not screen for sickle cell disease. 393 
However, although commonly associated with stroke elsewhere in sub-Saharan Africa, the 394 
prevalence of sickle cell disease in Malawi is low (<2%) and thus unlikely to have made a major 395 
contribution.[20] The absence of cerebral angiography limited our ability to refine the diagnosis of 396 
the cryptogenic group and thus further subdivide them into cardiac embolic or non-cardiac embolic 397 
causes. Indeed the latter could have represented undiagnosed HIV-associated vasculopathy. 398 
Furthermore, non-atherosclerotic vasculopathy and HIV-associated vasculitis could be 399 
manifestations of the same disease process at different stages of HIV infection, It is possible that the 400 
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hospital recruitment may have been biased against milder cases in the community. It is also possible 401 
that the risk of stroke seen in those starting ART may be related to being sick and not ART itself, 402 
although difficult to tease out, our proposed mechanism of IRIS is not dissimilar to other infections, 403 
in the very immunosuppressed, such as TB and Cryptococcus CNS infection.[15, 21]  Finally, CNS IRIS 404 
is associated with a poor prognosis and often fatal within days-weeks if untreated, leaving the 405 
possibility that ischemic stroke among those starting ART could have been underestimated if 406 
patients died before hospital admission.[14, 18]   407 
 408 
HIV-associated vasculopathy and opportunistic infections are common causes of HIV-related 409 
ischemic stroke. Furthermore, subtypes of HIV-associated vasculopathy may manifest as a result of 410 
an immune reconstitution-like syndrome after starting ART.  This study highlights the different 411 
phenotypes of HIV-associated vasculopathy and ties in with emerging data on neuro-inflammation 412 
pre- and post HIV-infection. Our understanding of the underlying mechanism and the role that HIV 413 
plays is incomplete, especially on better treated cohorts with cryptogenic stroke, and possibly ‘HIV-414 
associated’ atherosclerosis. This highlights the importance for future mechanistic studies to 415 
underpin the pathogenesis of these various subtypes and in time, pave the way for appropriate 416 
interventions . 417 
A better understanding of the mechanisms of this vasculopathy may point towards new treatments 418 
and thus, help to reduce the burden of stroke in this relatively young population. 419 
 420 
 421 
 422 
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Figure 1: Selection procedure and classification of cases 510 
Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory of 511 
‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined 512 
 513 
Figure 2: Clinical, radiologic and laboratory features among those starting ART  514 
(A) Etiology by ART status shows HIV-associated vasculopathy to be the most common etiology among those starting ART. 515 
(B) Radiologic examples of HIV-associated vasculopathy found among those starting ART: ID 32: Diffusion weighted ) [left] 516 
and Fluid Attenuated Inversion Recovery (FLAIR) [middle] sequences show a left Middle cerebral artery  infarct, while 517 
Doppler of the left common carotid artery [right] illustrates underlying concentric stenosis (≥70%) extending into the bulb.; 518 
ID 278 – Middle cerebral artery  infarct on Diffusion weighted [left] and T2-weighted [right] sequences; ID 46 and 85 - 519 
Diffusion weighted and FLAIR sequences show multifocal ischemic lesions in the basal ganglia and cortices. (C) Risk factors 520 
of immune reconstitution syndrome compared across the ART groups. Kruskal-Wallis non-parametric ANOVA was used to 521 
compare continuous variables across the ART treatment status groups. 522 
ART – antiretroviral treatment, CD4+ count – CD4+ T-lymphocyte count, IRIS – Immune Reconstitution Inflammatory 523 
Syndrome, CTE – Cardio-thromboembolism, O.I – Opportunistic infections, APS – Anti-phospholipid syndrome, 524 
Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory of 525 
‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined. 526 
 527 
Figure 3: Radio-histologic characteristics in patients presenting with HIV-associated vasculitis 528 
versus vasculitis related to TB meningitis after starting ART 529 
 530 
1.a-e;A 32 year old (5 months pregnant) female on ART for less than 6 months with an acute right arm monoparesis , 531 
dysphasia and headache. Her CD4+ count was 175cells/mm3 and HIV blood and CSF viral load were undetected on 532 
admission. Mild pleocytosis (White cell count 10 cells/mm3), moderately elevated protein (1.6mg/L) and a glucose ratio of 533 
0.48 was found on CSF examination. MRI 1.a-1.c confirmed an acute middle cerebral artery infarct. Histopathology (1.d-e) 534 
Multiple infarction of the cortical laminar type, marked periarteritis with foci of muscle necrosis, present in all sized 535 
arteries. There was lymphocytic meningitis but no granuloma or caseation or giant cells typical of TB meningitis. There was 536 
no CMV inclusion bodies and varicella zoster intrathecal IgG was negative. 2.a-e; A 34 year old female on ART for less than 537 
6 months with an acute right arm weakness, headache, neck ache and fever. CD4+ count was 128 cells/mm3 and HIV blood 538 
and CSF viral load on admission were 1.48 and 3.22 log10 copies/ml respectively. There was no CSF pleocytosis but a 539 
markedly elevated protein of 16.6mg/L and CSF glucose ratio of 0.28. MRI brain confirmed an acute infarct of the basal 540 
ganglia with mild hydrocephalus. Histopathology (2.d-e) Endarteritis obliterans of the small arteries with and a recent 541 
infarct of the basal ganglia.  There was widespread meningeal inflammation with confluent and discrete tuberculoid 542 
granulomas, typical caseating necrosis and Langhans’ giant cells. There were superficial Rich foci (i.e. tuberculous cerebritis 543 
adjacent to the meninges). Acid fast bacilli stain was negative but histology was characteristic of TB meningitis 544 
 545 
 546 
Supplement Figure 1: Histologic illustration of atherosclerotic vasculopathy: 547 
 548 
A 50 year old man on ART for greater than 6 months with an acute left hemiparesis. His CD4+ count was 192 cells/mm3 and HIV blood and 549 
CSF viral load were undetected on admission. He had no pleocytosis, a mildly elevated protein (0.9 mg/L) and a glucose ratio of 0.48 on 550 
CSF examination. A comprehensive etiological screen was unremarkable. Histopathology showed an acute infarct in the right cerebral 551 
hemisphere, and extensive atherosclerosis in all sized vessels, in both the left and right cerebral hemispheres. Sections of the right carotid 552 
artery had substantial atheroma. There was no acute thrombus. There was no HIV-associated encephalitis. 553 
 554 
 555 
 556 
 557 
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Figure 1: Selection procedure and classification of cases 
Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory 
of ‘cryptogenic embolism’ and ‘oth r cryptogenic’ ca not be etermined 
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564 Table 1: Clinical, and radiologic characteristics of ischemic stroke in HIV positive and negative 
cohorts 
 HIV positive (n=64) HIV negative 
(n=107) 
P value¥ 
Median Age (IQR) 40 (32,51) 66 (53,77) <0.001 
Male sex (%) 29 (45) 49 (46) 1.000 
Family history 9 (14) 17 (17) 0.403 
Hypertension (%) 27 (42) 89 (83) <0.001 
Diabetes (%) 2 (3) 14 (13) 0.032 
Hypercholesterolemia (%) 4 (7) 10 (10) 0.510 
Current smoker (%) 6 (9) 26 (24) 0.016 
Recent infection (%) 12 (19) 8 (8) 0.082 
ETOH intake (%) 13 (21) 14 (13) 0.379 
Cannabis use (%) 1 (2) 3 (3) 1.000 
Obesity (%) 
 T1 
 T2 
 T3 
 
14 (22) 
23 (37) 
26 (41) 
 
17 (16) 
33 (31) 
56 (53) 
 
0.496 
Median ankle brachial index 1.01 (0.96,1.01) 1.01 (0.94,1.06) 0.946 
Previous TIA 4 (6) 7 (7) 0.274 
Previous Stroke 4 (6) 15 (14) 0.244 
Radiologic Characteristics    
Acute/ subacute MRI lesions 
Cerebral cortex 
Cerebellum 
Brainstem 
Basal ganglia 
Periventricular white matter disease 
Other*** 
More than one focal lesion (%) 
 
39 (68) 
4 (7) 
6 (11) 
39 (68) 
24 (42) 
1 (2) 
12 (21) 
 
61 (66) 
3 (3) 
9 (10) 
39 (42) 
33 (36) 
2 (2) 
6 (8) 
 
0.721 
0.297 
0.866 
0.002 
0.418 
0.162 
0.034 
Stroke characteristics  
 Median NIH stroke scale NIHSS 12 (8,14) 11 (7,18) 0.813 
Etiology of Stroke (TOAST) 
 Large artery disease 
 Cardio-thromboembolism 
 Small vessel disease 
 Stroke of other determined∞ 
 Stroke of undetermined 
 
14 (21) 
4 (6) 
1 (1) 
31 (46) 
18 (27) 
 
14 (10) 
13 (9) 
 3 (2) 
15 (11) 
92 (67) 
 
 
 
<0.001 
Hospital Fatality 11 (17) 10 (9) 0.152 
** Cerebral cortex includes frontal, temporal, occipital and parietal lobe 
***Corpus callosum, hypothalamus, pituitary, cranio-cervical junction 
¥ Categorical variables were analyzed with Fisher’s two-sided exact test. Kruskal-Wallis non-parametric ANOVA was used to 
compare continuous variables 
∞Stroke of Other determined cause in the HIV negative group includes; 7 – Probable antiphospholipid syndrome, 4- 
Syphilis, 2 –Varicella zoster, 1 – TB, 1- Probable vasculitis.  
†See Table 3 for HIV-associated stroke 
T=Tertile 
cp/ml=copies/ml 
Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory 
of ‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined. 
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Table 2: Clinical features of the different etiologies found in HIV-related ischemic stroke† 
 HIV-associated vasculopathy¤ 
N=23 
Opportunistic 
Infections 
N=16 
 
 
Anti-phospholipid 
syndrome 
N=6 
Cardio-thrombo 
embolism 
N=4 
Cryptogenic* 
stroke n=11 
P value¥ 
Atherosclerotic 
vasculopathy 
(n=7) 
Non-
atherosclerotic 
vasculopathy 
(n=7) 
 HIV-associated 
vasculitis 
(n=9) 
Median age (IQR) 60 (50,68) 33 (24,42) 35 (32,42) 35 (28,41) 42 (32,52) 58 (48,69) 44 (31,54) <0.001 
Male (%) 4 (57) 4 (57) 4 (44) 5 (31) 4 (67) 2 (50) 2 (50) 0.606 
ART status (%) 
 Untreated 
 <6 months on treatment 
 ≥6 months on treatment 
 
4 (57) 
0  
3 (43) 
 
4 (57) 
3 (43) 
0 
 
2 (22) 
6 (67) 
1 (11) 
 
12 (75) 
3 (19) 
1 (6) 
 
4 (67) 
2 (33) 
0 
 
2 (50) 
1 (25) 
1 (25) 
 
7 (64) 
1 (9) 
3 (27) 
 
0.048 
CD4+ T-lymphocyte count mm3 271 (192,318) 248 (218,305) 88 (15,117) 131 (61,294) 93 (63,159) 302 (240,558) 204 (51,458) 0.031 
HIV blood viral load log10 cp/ml 3.1 (0,4.4) 3.7 (1.5,4.3) 0 (0,2.5) 3.5 (2.4,4.6) 4.7 (2.0,5.3) 1.5 (0,4.0) 1.5 (0,4.6) 0.183 
Haemoglobin (g/dl) 12.0 (9.0,15.0) 11.0 (9.0,15.0) 12.0 (10.0,14.0) 12.0 (10.0,13.0) 10.0 (9.0,12.0) 14.0 (13.0,15.0) 12.0 (9.0,13.0) 0.720 
 
NIH stroke scale  
 
12 (7,14) 
 
11(8,17) 
 
13(12,18) 
 
13 (8,16) 
 
10 (7,12) 
 
9 (8,11) 
 
11 (6,14) 
 
0.596 
Hospital fatality 2 (29) 1 (14) 2 (22) 3 (19) 1 (17) 0 2 (18) 0.955 
†Continuous variable presented as median with interquartile ranges 
¤ Small vessel disease (n=1), Multifactorial stroke (n=1) and Inconclusive (n=2) were not included in the analysis. 
¥ Categorical variables were analyzed with Fisher’s two-sided exact test. Kruskal-Wallis non-parametric ANOVA was used to compare continuous variables 
ART – antiretroviral treatment  
Cryptogenic* - * indicates that non-invasive or invasive angiography was not done and therefore the subcategory of ‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined. 
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Table 2: Clinical features of the different etiologies found in HIV-related ischemic stroke† 
 HIV-associated vasculopathy¤ 
N=23 
Opportunistic 
Infections 
N=16 
 
 
Anti-phospholipid 
syndrome 
N=6 
Cardio-thrombo 
embolism 
N=4 
Cryptogenic* 
stroke n=11 
P value¥ 
Atherosclerotic 
vasculopathy 
(n=7) 
Non-
atherosclerotic 
vasculopathy 
(n=7) 
 HIV-associated 
vasculitis 
(n=9) 
Median age (IQR) 60 (50,68) 33 (24,42) 35 (32,42) 35 (28,41) 42 (32,52) 58 (48,69) 44 (31,54) <0.001 
Male (%) 4 (57) 4 (57) 4 (44) 5 (31) 4 (67) 2 (50) 2 (50) 0.606 
ART status (%) 
 Untreated 
 <6 months on treatment 
 ≥6 months on treatment 
 
4 (57) 
0  
3 (43) 
 
4 (57) 
3 (43) 
0 
 
2 (22) 
6 (67) 
1 (11) 
 
12 (75) 
3 (19) 
1 (6) 
 
4 (67) 
2 (33) 
0 
 
2 (50) 
1 (25) 
1 (25) 
 
7 (64) 
1 (9) 
3 (27) 
 
0.048 
CD4+ T-lymphocyte count mm3 271 (192,318) 248 (218,305) 88 (15,117) 131 (61,294) 93 (63,159) 302 (240,558) 204 (51,458) 0.031 
HIV blood viral load log10 cp/ml 3.1 (0,4.4) 3.7 (1.5,4.3) 0 (0,2.5) 3.5 (2.4,4.6) 4.7 (2.0,5.3) 1.5 (0,4.0) 1.5 (0,4.6) 0.183 
Haemoglobin (g/dl) 12.0 (9.0,15.0) 11.0 (9.0,15.0) 12.0 (10.0,14.0) 12.0 (10.0,13.0) 10.0 (9.0,12.0) 14.0 (13.0,15.0) 12.0 (9.0,13.0) 0.720 
 
NIH stroke scale NIHSS 
 
12 (7,14) 
 
11(8,17) 
 
13(12,18) 
 
13 (8,16) 
 
10 (7,12) 
 
9 (8,11) 
 
11 (6,14) 
 
0.596 
Hospital fatality 2 (29) 1 (14) 2 (22) 3 (19) 1 (17) 0 2 (18) 0.955 
†Continuous variable presented as median with interquartile ranges 
¤ Small vessel disease (n=1), Multifactorial stroke (n=1) and Inconclusive (n=2) were not included in the analysis. 
¥ Categorical variables were analyzed with Fisher’s two-sided exact test. Kruskal-Wallis non-parametric ANOVA was used to compare continuous variables 
ART – antiretroviral treatment  
Cryptogenic* - * indicates that non-invasive or invasive angiography was not done and therefore the subcategory of ‘cryptogenic embolism’ and ‘other cryptogenic’ cannot be determined. 
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Figure 2: Clinical, radiologic and laboratory features among those starting ART  
(A) Etiology by ART status shows HIV-associated vasculopathy to be the most common etiology among those starting ART. (B) Radiologic examples of HIV-associated vasculopathy found 
among those starting ART: ID 32: Diffusion weighted (DWI) [left] and Fluid Attenuated Inversion Recovery (FLAIR) [middle] sequences show a left MCA Middle cerebral artery  infarct, 
while Doppler of the left common carotid artery [right] illustrates underlying concentric stenosis (≥70%) extending into the bulb.; ID 278 -– Middle cerebral artery MCA infarct on 
Diffusion weighted DWI [left] and T2-weighted2W [right] sequences; ID 46 and 85 - Diffusion weighted DWI and FLAIR sequences show multifocal ischemic lesions in the basal ganglia 
and cortices. (C) Risk factors of immune reconstitution syndrome compared across the ART groups.  Kruskal-Wallis non-parametric ANOVA was used to compare continuous variables across the 
ART treatment status groups. 
ART – antiretroviral treatment, CD4+ count – CD4+ T-lymphocyte count, IRIS – Immune Reconstitution Inflammatory Syndrome, CTE – Cardio-thromboembolism, O.I – Opportunistic 
infections, APS – Anti-phospholipid syndrome, Cryptogenic* - * indicates that non-invasive or invasive angiography has not been done and therefore the subcategory of ‘cryptogenic 
embolism’ and ‘other cryptogenic’ cannot be determined. 
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Figure 3: Radio-histologic characteristics in patients presenting with HIV-associated vasculitis 
versus vasculitis related to TB meningitis after starting ART 
 
1.a-e;A 32 year old (5 months pregnant) female on ART for less than 6 months with an acute right arm monoparesis , dysphasia and 
headache. Her CD4+ count was 175cells/mm3 and HIV blood and CSF viral load were undetected on admission. Mild pleocytosis 
(White cell countCC 10 cells/mm3), moderately elevated protein (1.6mg/L) and a glucose ratio of 0.48 was found on CSF examination. 
MRI 1.a-1.c confirmed an acute middle cerebral artery infarct. Histopathology (1.d-e) Multiple infarction of the cortical laminar type, 
marked periarteritis with foci of muscle necrosis, present in all sized arteries. There was lymphocytic meningitis but no granuloma or 
caseation or giant cells typical of  TB meningitisTuberculous meningitis (TBM). There was no CMV inclusion bodies and varicella zoster 
intrathecal IgG was negative. 2.a-e; A 34 year old female on ART for less than 6 months with an acute right arm weakness, headache, 
neck ache and fever. CD4+ count was 128 cells/mm3 and HIV blood and CSF viral load on admission were 1.48 and 3.22 log10 copies/ml 
respectively. There was no CSF pleocytosis but a markedly elevated protein of 16.6mg/L and CSF glucose ratio of 0.28. MRI brain 
confirmed an acute infarct of the basal ganglia with mild hydrocephalus. Histopathology (2.d-e) Endarteritis obliterans of the small 
arteries with and a recent infarct of the basal ganglia.  There was widespread meningeal inflammation with confluent and discrete 
tuberculoid granulomas, typical caseating necrosis and Langhans’ giant cells. There were superficial Rich foci (i.e. tuberculous 
cerebritis adjacent to the meninges). Acid fast bacilli stain was negative but histology was characteristic of TB meningitisTBM. 
 
 
 
 
 
 
 
 
 
NIHSS – National Institutes of Health Stroke Scale   APS - Antiphospholipid syndrome  
CXR  - Chest x-ray      TB – Mycobacterium Tuberculosis    
TBM - Mycobacterium Tuberculosis meningitis   VZV – Varicella zoster virus     
ECG – electrocardiogram     WCC – White cell count    
RCC – Red cell count      CRAG – cryptococcal antigen    
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Supplement Figure 1: Histologic illustration of 
atherosclerotic vasculopathy: 
 
A 50 year old man on ART for greater than 6 months with an acute left 
hemiparesis. His CD4+ count was 192 cells/mm3 and HIV blood and CSF viral 
load were undetected on admission. He had no pleocytosis, a mildly 
elevated protein (0.9 mg/L) and a glucose ratio of 0.48 on CSF examination. 
A comprehensive etiological screen was unremarkable. Histopathology 
showed an acute infarct in the right cerebral hemisphere, and extensive 
atherosclerosis in all sized vessels, in both the left and right cerebral 
hemispheres. Sections of the right carotid artery had substantial atheroma. 
There was no acute thrombus. There was no HIV-associated encephalitis. 
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stroke  
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to be addressed in a further revision. 
 
1. In figure 1, the value for all opportunistic infections, "16 (25)" is misaligned with VZV; please correct. 
Thanks for highlighting. This has now been amended.  
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3. Insert limits: for Major Articles, 7 in print (tables and figures, with no more than 4 panels per figure), no 
more than 25 MB of online-only supplementary data; for Brief Reports, 2 in print (tables and figures, with no 
more than 4 panels per figure), no more than 25 MB of online-only supplementary data.  
We now comply with these limits 
 
4. Use Word to make tables. Upload figures in their native file formats, i.e., the format in which the image was 
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